MOLECULAR STUDIES OF HUMAN MELANOMA ANTIGEN

Information

  • Research Project
  • 3175291
  • ApplicationId
    3175291
  • Core Project Number
    R01CA037440
  • Full Project Number
    5R01CA037440-03
  • Serial Number
    37440
  • FOA Number
  • Sub Project Id
  • Project Start Date
    9/15/1983 - 41 years ago
  • Project End Date
    2/28/1986 - 38 years ago
  • Program Officer Name
  • Budget Start Date
    3/1/1985 - 39 years ago
  • Budget End Date
    2/28/1986 - 38 years ago
  • Fiscal Year
    1985
  • Support Year
    3
  • Suffix
  • Award Notice Date
    -

MOLECULAR STUDIES OF HUMAN MELANOMA ANTIGEN

We intend to investigate the immunochemistry, structure, and function of human melanoma-associated antigen p97, one of the best characterized and most tumor-specific of the human tumor-associated antigens so far identified by monoclonal antibodies. Our goal is to use p97 as a model so as to obtain insight into the nature of human tumor-associated antigens and to open the way to more effective diagnosis and therapy of human cancer. For the entire project period we have three specific aims: I. Immunochemistry. We intend: (1) to generate and characterize monoclonal antibodies to additional epitopes of native and denatured p97; (2) to synthesize peptides based on the amino acid sequence of p97 for use as immunogens; and (3) to obtain anti-idiopathic antibodies to mimic conformational epitopes of p97 for use as immunogens. II. Structure. Our structural studies of p97 will comprise: (1) amino acid sequencing; (2) investigation of post-translational modifications, particularly carbohydrate and phosphate; and (3) examination of its structure at the cell surface. III. Function. We shall investigate: (1) the putative role of p97 in iron uptake, particularly to determine whether p97 offers an alternative to the transferrin receptor as a means of iron uptake by melanoma cells and (2) the association of p97 with neoplasia, particularly whether the presence of p97 in large amounts in melanomas is a consequence (or cause) of neoplastic transformation or rapid growth. (AG)

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    R01
  • Administering IC
    CA
  • Application Type
    5
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    396
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    EI
  • Study Section Name
    Experimental Immunology Study Section
  • Organization Name
    ONCOGEN
  • Organization Department
  • Organization DUNS
  • Organization City
    SEATTLE
  • Organization State
    WA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    98121
  • Organization District
    UNITED STATES